An FDA panel recently recommended approval of Kynapid but rejected giving a recommendation to Pulzium to treat atrial fibrillation (AF), a condition in which panel of federal advisers this week told the FDA that it should approve Kynapid and Pulzium to treat atrial fibrillation (AF).